By Dr Angela Wittelsberger, Dr Hugh Laverty and Dr Michel Goldman
The development of a new medicine is risky and expensive. It often takes 15 years and a $1billion investment for a compound to navigate its way along the development process. Only 8% of candidates make it to market and benefiting the patient.
In order to maintain a flow of innovative medicines there is a growing realisation that companies cannot allow the status quo to remain. The need to identify sources of knowledge and expertise outside of their own organisations is paramount.
Acute Kidney Injury (AKI) is a devastating disease characterised by a rapid loss of kidney function resulting in inability to maintain fluid, electrolyte and acidbase balance. AKI is particularly common in patients admitted to the Intensive Care Unit where incidence rates between 22% to as high as 67% of admissions have been reported.
The UK, Europe and the US are world leaders in research and innovation. They have world-leading universities, research institutes and scientific enterprises, supported by a public and private sector that has continued to invest, despite the global economic downturn.
Since publication of Lipinskiâs Rule of Five (Ro5) in 1997 we have seen the growth of a minor industry dedicated to generating new ârulesâ for drug discovery. Fuelled by âRo5 envyâ, these rules are usually based on simple calculated compound characteristics and define criteria for the selection of compounds in drug discovery. But, can a generic rule be used to reliably select compounds for drug discovery?
Screening centres in academic institutions and non-profit organisations have become an established mechanism to exploit novel targets and neglected diseases and to identify chemical probes. Where centres have a disease focus, their main expertise resides in cancer and phenotypic screens, with screening experience greatest for kinases, phenotypic approaches and protein-protein interactions.